KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Inventory (2017 - 2025)

Historic Change in Inventory for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $30.8 million.

  • Amneal Pharmaceuticals' Change in Inventory fell 2851.87% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.8 million, marking a year-over-year increase of 1691.94%. This contributed to the annual value of $130.5 million for FY2024, which is 344.58% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Change in Inventory stood at $30.8 million, which was down 2851.87% from $22.8 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Change in Inventory high stood at $52.0 million for Q4 2024, and its period low was -$16.6 million during Q4 2021.
  • Over the past 5 years, Amneal Pharmaceuticals' median Change in Inventory value was $23.2 million (recorded in 2024), while the average stood at $25.0 million.
  • Examining YoY changes over the last 5 years, Amneal Pharmaceuticals' Change in Inventory showed a top increase of 63012.96% in 2021 and a maximum decrease of 15029.64% in 2021.
  • Amneal Pharmaceuticals' Change in Inventory (Quarter) stood at -$16.6 million in 2021, then soared by 166.57% to $11.1 million in 2022, then surged by 108.58% to $23.1 million in 2023, then soared by 125.14% to $52.0 million in 2024, then plummeted by 40.74% to $30.8 million in 2025.
  • Its last three reported values are $30.8 million in Q3 2025, $22.8 million for Q2 2025, and $13.3 million during Q1 2025.